Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integrum ABFRA:6Y1 +0.43%56 Receivables Turnover is 0.91 as of Apr. 2026. GuruFocus rates FRA:6Y1 with a GF Score™ of 56/100 and a GF Value™ of €1.54 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Integrum AB ranks worse than 81.26% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Integrum AB's Revenue for the
three
months ended in Apr. 2026 was €2.31 Mil. Integrum AB's average Accounts Receivable for the
three
months ended in Apr. 2026 was €2.53 Mil.
Hence, Integrum AB's Receivables Turnover for the
three
months ended in Apr. 2026 was 0.91.
Integrum AB (FRA:6Y1) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Integrum AB Receivables Turnover Related Terms
Integrum AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Integrum AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6Y1 vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Integrum AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrum AB Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integrum AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Integrum AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrum AB (FRA:6Y1) has a Receivables Turnover of 0.91 as of Apr. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Integrum AB and its competitors. According to the industry distribution chart, Integrum AB ranks #659 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 81.3%.
Is Integrum AB's Receivables Turnover too high?
Integrum AB's current Receivables Turnover is 0.91. The Medical Devices & Instruments industry median Receivables Turnover is 5.60. Integrum AB's value of 0.91 is 83.8% below this industry median. Based on the distribution chart, Integrum AB ranks #659 out of 811 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Integrum AB has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrum AB's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Integrum AB ranks #659 out of 811 companies for Receivables Turnover. This places Integrum AB in the lower half of its industry. The industry median Receivables Turnover is 5.60. Integrum AB's value of 0.91 is 83.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.60, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integrum AB's current Receivables Turnover of 0.91 is 83.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Integrum AB and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrum AB's current Receivables Turnover is 0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrum AB stock overvalued right now?
Based on GuruFocus' analysis, Integrum AB (FRA:6Y1) is currently considered Possible Value Trap. The stock's GF Value™ is €1.54, compared to a current price of €0.71 — trading 54% below its estimated fair value. The current Receivables Turnover is 0.91 and 83.8% below the Medical Devices & Instruments industry median of 5.60. Integrum AB's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Integrum AB (FRA:6Y1), the current Receivables Turnover is 0.91 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrum AB (FRA:6Y1) Overvalued in 2026?
Based on GuruFocus' analysis, Integrum AB stock appears to be undervalued.
The current stock price of €0.71 is trading 54% below its estimated GF Value™ of €1.54.
GuruFocus considers Integrum AB to be Possible Value Trap.
Key valuation signals for FRA:6Y1:
Receivables Turnover: 0.91
GF Value™: €1.54 vs. price of €0.71 (54% below fair value)
Industry Position: 83.8% below the Medical Devices & Instruments median (#659 of 811)
No single metric tells the full story. See the FRA:6Y1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrum AB provides the system for bone-anchored prostheses that improves the lives of people with amputations. Its solutions include OPRA implant system, Neural prosthetics, Phantom limb pain treatment, and Prosthetic components. The company is also engaged in developing technology for mind-controlled prostheses and treatment for phantom limb pain.
56GF Score
Get the complete analysis for FRA:6Y1
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6Y1 has been successfully added to your 
